Myeloid neoplasms: Focused analysis to advance understanding
A detailed view of the path ahead
For patients affected by acute myeloid leukemia (AML) and other myeloid neoplasms, understanding the unique genetic characteristics of their cancer is crucial to choosing the most effective treatment. Identification of variants associated with prognosis and treatment response allows for tailored interventions that have the potential to improve patients’ chances of long-term survival. But with more gene-specific and targeted treatments available for AML than ever before, determining the best therapy for patients can be complicated.
47
47 genes included in our myeloid neoplasms comprehensive panel
11
11 genes included in our focused AML panel
4
4 genes included in our therapeutic gene-mutation panel
NGSFX
NGSFX Flexible, reflexive test option that reanalyzes remaining genes from our 47-gene panel after a focused 4- or 11-gene panel is performed
Precise, patient-focused testing
MayoComplete next-generation sequencing for myeloid neoplasms quickly delivers clear answers that cut through the confusion. Developed by highly focused teams of laboratory and hematology specialists and carefully curated to include only actionable variants, our testing provides detailed answers to guide each patient’s unique journey.
In addition to comprehensive and focused next-generation sequencing panels, we offer molecular testing to detect rare variants and evaluate measurable residual disease (MRD).
Learn more:
Learn more Next-generation sequencing for myeloid neoplasms
Inspiring confidence through unparalleled expertise
Combining the expertise of world-renowned laboratory scientists and physicians, Mayo Clinic Laboratories provides answers for the most serious hematologic conditions. Our integration with the clinical hematology practice at Mayo Clinic supports the development of innovative, clinically meaningful assays that provide accurate, detailed answers to elevate patient care.
“Next-generation sequencing provides comprehensive genetic profiling. We can detect different variant classes. We can detect these across multiple genes, and we can do this across different myeloid neoplasms all at once.”
David Viswanatha, M.D., Professor of Laboratory Medicine and Pathology, Division of Hematopathology
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.
VEXAS syndrome is a severe autoinflammatory disease that results in a spectrum of rheumatologic and hematologic conditions. The underlying cause of newly identified VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome — somatic mutations in the UBA1 gene of blood cells — was discovered at the National Institutes of Health (NIH) in 2020. Within six months, Mayo Clinic Laboratories was able to add a UBA1 test to the MayoComplete panel, as the team simultaneously worked on a single gene assay to allow doctors to test specifically for UBA1 mutations to screen patients for VEXAS syndrome. The team opted for a droplet digital PCR test — a novel and highly accurate approach to testing for UBA1 gene mutations.
In this month's "Hot Topic," David Viswanatha, M.D., discusses updates to Mayo Clinic's next-generation sequencing (NGS) for myeloid neoplasm evaluation, involving new test targets, the rationale for new genetic regions, alignments with the World Health Organization (WHO) guidelines and germline predisposition targets.
Rong He, M.D., describes how Mayo Clinic Laboratories’ NPM1Q assay detects all known forms of a genetic mutation found in about 30% of people with acute myeloid leukemia, or AML. Identifying the NPM1 mutation is critical for clinical decision-making.
Learn more
Let us help you better define your patients’ diagnosis, prognosis, and therapeutic approach.
Learn more about our complete menu of advanced molecular testing for myeloid neoplasms. Schedule an appointment with one of our team members.
